Healthcare Equipment and Supplies
Company Overview of Nanomix, Inc.
Nanomix, Inc., a nanoelectronic detection company, develops and manufactures Sensation technology based detection devices for biomolecule and respiratory detection applications. The company offers an ultrasensitive cardiac troponin assay to evaluate heart muscle damage; and an eNO Asthma Management System, a stand-alone breath analysis system for managing asthma that measures exhaled nitric oxide. It also provides environmental monitors to detect low levels of industrial gas for environmental monitoring and demand controlled ventilation; and carbon nanotubes for the detection of various biomolecules and gases a single device with different chemistries. The company’s products are used in the ...
5980 Horton Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Nanomix, Inc.
Chief Executive Officer and President
Chief Financial Officer and Vice President of Finance
Compensation as of Fiscal Year 2014.
Nanomix, Inc. Key Developments
Nanomix, Inc. Appoints Brian Jung as Vice President of Finance and Chief Financial Officer
Jun 30 14
Nanomix, Inc. announced the appointment of Brian Jung as Vice President of Finance and Chief Financial Officer. Mr. Jung brings significant financial and executive experience to Nanmix, having served in CFO and executive roles for several healthcare and life science companies.
Nanomix Inc. Closes Private Financing for Approximately $12 Million
Jan 30 14
Nanomix Inc. announced that is has closed private financing for approximately $12 million. The financing, received from a strategic corporate partner and existing investors, will fund the completion of development, registration clinical trials, and commercial launch of the company's mobile diagnostic platform and initial assays.
Nanomix, Inc. Initiates Clinical Testing of Point of Care IVD Cardiac Panel
Feb 11 13
Nanomix, Inc. announced that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel. The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and H-FABP, biomarkers often used as an aid in the diagnosis of myocardial infarction (MI). The initial testing will be conducted with approximately 170 normally healthy subjects and will provide baseline performance information that will form the basis of future registration clinical studies. Chest pain is the second leading cause of admittance to Emergency Departments in the US. An early and accurate diagnosis of chest pain complaints is key to achieving improved patient outcomes through earlier treatment intervention. The Omega-3 handheld system is designed for use in the Emergency Department and by pre-hospital First Responders in the field to speed the diagnosis of an MI. The combination of a handheld electronic reader and wholly contained cartridge allow the cardiac test panel to be performed at the point of patient contact, avoiding delays associated with transporting samples to laboratory for traditional testing.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 30, 2014
Most Searched Private Companies
Sponsored Financial Commentaries